Medtronic scores expanded indication for CRT-D devices; MedPro Imaging jumps into veterinary market;

@FierceMedDev: BBC News--Medical device hack attacks may kill, researchers warn. Story | Follow @FierceMedDev

> The FDA has blessed an expanded indication for Medtronic's ($MDT) cardiac resynchronization therapy with implantable cardioverter defibrillator (CRT-D) devices. The advanced therapy can now be used earlier, in a mildly symptomatic heart failure patient population, potentially improving survival and preventing disease progression. Medtronic release

> MedPro Imaging has unveiled a new division offering a variety of ultrasound products and repair services dedicated to the veterinary market. MedPro Vet, as the unit is called, is also launching the first dedicated veterinary probe repair lab in the world. MedPro Imaging release

> Boston Scientific ($BSX) has announced CE Mark approval and European market launch of its INGENIO and ADVANTIO pacemakers and INVIVE cardiac resynchronization therapy pacemakers. Boston Scientific release

> Cook Group has bought Indianapolis-based General BioTechnology, which employs about 20 people. Terms of the deal were not announced. Item

> Increasing numbers of diabetics and elderly patients are causing the demand for negative pressure wound therapy to rise, thereby improving the technology, according to a new report by medical intelligence company GlobalData. Release

And Finally... Israel's life sciences firms' 2011 results saw the line drawn between the successful and the not-so-successful, especially in the medical device industry. Some companies flourished, while others sank and may not recover. News

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.